Jul 10, 2024, 08:31
ASCO – Why biomarkers are needed to optimize outcomes and avoid toxicities
ASCO shared on X:
“Though novel therapies have improved survival in patients with mUC, many will still develop resistance. For ASCO Daily News, Enrique Grande, Patrizia Giannatempo and Deborah Mukherji discuss why biomarkers are needed to optimize outcomes and avoid toxicities.”
Read further.
Source: ASCO/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 14:40
Nov 14, 2024, 14:39
Nov 14, 2024, 14:28
Nov 14, 2024, 14:05
Nov 14, 2024, 13:49